BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

836 related articles for article (PubMed ID: 28799876)

  • 21. Association Between Radiation Necrosis and Tumor Biology After Stereotactic Radiosurgery for Brain Metastasis.
    Miller JA; Bennett EE; Xiao R; Kotecha R; Chao ST; Vogelbaum MA; Barnett GH; Angelov L; Murphy ES; Yu JS; Ahluwalia MS; Suh JH; Mohammadi AM
    Int J Radiat Oncol Biol Phys; 2016 Dec; 96(5):1060-1069. PubMed ID: 27742540
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Survival of melanoma patients treated with targeted therapy and immunotherapy after systematic upfront control of brain metastases by radiosurgery.
    Gaudy-Marqueste C; Dussouil AS; Carron R; Troin L; Malissen N; Loundou A; Monestier S; Mallet S; Richard MA; Régis JM; Grob JJ
    Eur J Cancer; 2017 Oct; 84():44-54. PubMed ID: 28783540
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Toxicity and outcomes of melanoma brain metastases treated with stereotactic radiosurgery: the risk of subsequent symptomatic intralesional hemorrhage exceeds that of radiation necrosis.
    Jablonska PA; Muniz T; Ribeiro M; Liu ZA; Ye XY; Devaraja K; Laperriere N; Millar BA; Conrad T; Kongkham P; Butler M; Shultz DB
    J Neurooncol; 2023 Aug; 164(1):199-209. PubMed ID: 37552363
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Repeat stereotactic radiosurgery as salvage therapy for locally recurrent brain metastases previously treated with radiosurgery.
    McKay WH; McTyre ER; Okoukoni C; Alphonse-Sullivan NK; Ruiz J; Munley MT; Qasem S; Lo HW; Xing F; Laxton AW; Tatter SB; Watabe K; Chan MD
    J Neurosurg; 2017 Jul; 127(1):148-156. PubMed ID: 27494815
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Stereotactic radiosurgery combined with nivolumab or Ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicity.
    Minniti G; Anzellini D; Reverberi C; Cappellini GCA; Marchetti L; Bianciardi F; Bozzao A; Osti M; Gentile PC; Esposito V
    J Immunother Cancer; 2019 Apr; 7(1):102. PubMed ID: 30975225
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of radiotherapy and sequencing of systemic therapy on survival outcomes in melanoma patients with previously untreated brain metastasis: a multicenter DeCOG study on 450 patients from the prospective skin cancer registry ADOREG.
    Franklin C; Mohr P; Bluhm L; Grimmelmann I; Gutzmer R; Meier F; Garzarolli M; Weichenthal M; Pfoehler C; Herbst R; Terheyden P; Utikal J; Ulrich J; Debus D; Haferkamp S; Kaatz M; Forschner A; Leiter U; Nashan D; Kreuter A; Sachse M; Welzel J; Heinzerling L; Meiss F; Weishaupt C; Gambichler T; Weyandt G; Dippel E; Schatton K; Celik E; Trommer M; Helfrich I; Roesch A; Zimmer L; Livingstone E; Schadendorf D; Horn S; Ugurel S
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35688555
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients.
    Amaral T; Kiecker F; Schaefer S; Stege H; Kaehler K; Terheyden P; Gesierich A; Gutzmer R; Haferkamp S; Uttikal J; Berking C; Rafei-Shamsabadi D; Reinhardt L; Meier F; Karoglan A; Posch C; Gambichler T; Pfoehler C; Thoms K; Tietze J; Debus D; Herbst R; Emmert S; Loquai C; Hassel JC; Meiss F; Tueting T; Heinrich V; Eigentler T; Garbe C; Zimmer L;
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32221017
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.
    Chen L; Douglass J; Kleinberg L; Ye X; Marciscano AE; Forde PM; Brahmer J; Lipson E; Sharfman W; Hammers H; Naidoo J; Bettegowda C; Lim M; Redmond KJ
    Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):916-925. PubMed ID: 29485071
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic factors for melanoma brain metastases treated with stereotactic radiosurgery.
    Bian SX; Routman D; Liu J; Yang D; Groshen S; Zada G; Trakul N; Wong MK; Yu C; Chang EL
    J Neurosurg; 2016 Dec; 125(Suppl 1):31-39. PubMed ID: 27903181
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Current Treatment of Melanoma Brain Metastasis.
    Rishi A; Yu HM
    Curr Treat Options Oncol; 2020 Apr; 21(6):45. PubMed ID: 32350685
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Stereotactic radiosurgery for patients with multiple brain metastases: a case-matched study comparing treatment results for patients with 2-9 versus 10 or more tumors.
    Yamamoto M; Kawabe T; Sato Y; Higuchi Y; Nariai T; Watanabe S; Kasuya H
    J Neurosurg; 2014 Dec; 121 Suppl():16-25. PubMed ID: 25434933
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Outcomes after stereotactic radiosurgery of brain metastases in patients with malignant melanoma and validation of the melanoma molGPA.
    Kessel KA; Deichl A; Gempt J; Meyer B; Posch C; Diehl C; Zimmer C; Combs SE
    Clin Transl Oncol; 2021 Oct; 23(10):2020-2029. PubMed ID: 33993415
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Toxicity and efficacy of Gamma Knife radiosurgery for brain metastases in melanoma patients treated with immunotherapy or targeted therapy-A retrospective cohort study.
    Gatterbauer B; Hirschmann D; Eberherr N; Untersteiner H; Cho A; Shaltout A; Göbl P; Fitschek F; Dorfer C; Wolfsberger S; Kasprian G; Höller C; Frischer JM
    Cancer Med; 2020 Jun; 9(11):4026-4036. PubMed ID: 32249551
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multimodality treatment of melanoma brain metastases incorporating stereotactic radiosurgery (SRS).
    Samlowski WE; Watson GA; Wang M; Rao G; Klimo P; Boucher K; Shrieve DC; Jensen RL
    Cancer; 2007 May; 109(9):1855-62. PubMed ID: 17351953
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Stereotactic radiosurgery and ipilimumab for patients with melanoma brain metastases: clinical outcomes and toxicity.
    Diao K; Bian SX; Routman DM; Yu C; Ye JC; Wagle NA; Wong MK; Zada G; Chang EL
    J Neurooncol; 2018 Sep; 139(2):421-429. PubMed ID: 29696531
    [TBL] [Abstract][Full Text] [Related]  

  • 36. BRAF-V600 mutational status affects recurrence patterns of melanoma brain metastasis.
    Maxwell R; Garzon-Muvdi T; Lipson EJ; Sharfman WH; Bettegowda C; Redmond KJ; Kleinberg LR; Ye X; Lim M
    Int J Cancer; 2017 Jun; 140(12):2716-2727. PubMed ID: 27342756
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Radiosurgery/stereotactic radiotherapy in combination with immunotherapy and targeted agents for melanoma brain metastases.
    Trino E; Mantovani C; Badellino S; Ricardi U; Filippi AR
    Expert Rev Anticancer Ther; 2017 Apr; 17(4):347-356. PubMed ID: 28277101
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Survival of melanoma patients with brain metastases treated with ipilimumab and stereotactic radiosurgery.
    Tazi K; Hathaway A; Chiuzan C; Shirai K
    Cancer Med; 2015 Jan; 4(1):1-6. PubMed ID: 25164960
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Volume of Disease as a Predictor for Clinical Outcomes in Patients With Melanoma Brain Metastases Treated With Stereotactic Radiosurgery and Immune Checkpoint Therapy.
    Burke AM; Carrasquilla M; Jean WC; Collins BT; Anaizi AN; Atkins MB; Gibney GT; Collins SP
    Front Oncol; 2021; 11():794615. PubMed ID: 35096594
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery.
    Qian JM; Yu JB; Kluger HM; Chiang VL
    Cancer; 2016 Oct; 122(19):3051-8. PubMed ID: 27285122
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 42.